OncoMatch/Clinical Trials/NCT04532281
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
Is NCT04532281 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Murine CD19 CAR-T cells for acute lymphoblastic leukemia.
Treatment: Murine CD19 CAR-T cells — A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
CD19+ B-ALL
Required: CD19 positive
B-NHL (all listed subtypes are B-cell lymphomas and presumed CD19+ for CAR-T eligibility)
Excluded: BCR-ABL1 fusion
Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify